GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rain Oncology Inc (NAS:RAIN) » Definitions » Net Debt Paydown Yield %

Rain Oncology (Rain Oncology) Net Debt Paydown Yield % : 0.16% (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rain Oncology Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Rain Oncology's Net Debt Paydown Yield % was 0.16%.


Rain Oncology Net Debt Paydown Yield % Historical Data

The historical data trend for Rain Oncology's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rain Oncology Net Debt Paydown Yield % Chart

Rain Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net Debt Paydown Yield %
- - - 0.04

Rain Oncology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.04 0.04 0.31 0.22

Competitive Comparison of Rain Oncology's Net Debt Paydown Yield %

For the Biotechnology subindustry, Rain Oncology's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rain Oncology's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rain Oncology's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Rain Oncology's Net Debt Paydown Yield % falls into.



Rain Oncology Net Debt Paydown Yield % Calculation

Rain Oncology's Net Debt Paydown Yield % for the quarter that ended in Sep. 2023 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 0.36-0.29 )/31.34857826
=0.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Rain Oncology  (NAS:RAIN) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Rain Oncology Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of Rain Oncology's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rain Oncology (Rain Oncology) Business Description

Traded in Other Exchanges
N/A
Address
8000 Jarvis Avenue, Suite 204, Newark, CA, USA, 94560
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Executives
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Josephine Bruce officer: Principal Fin. & Acc. Officer 8000 JARVIS AVENUE, SUITE 204, NEWARK CA 94560
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Boxer Capital, Llc other: See remarks. 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis other: See remarks. PO BOX N7776, LYFORD BAHAMAS
Aaron I. Davis director 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Erik Atkisson officer: General Counsel and CCO C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Avanish Vellanki director, officer: President and CEO 8000 JARVIS AVENUE, SUITE 204, NEWARK CA 94560
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Gorjan Hrustanovic director C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472

Rain Oncology (Rain Oncology) Headlines

From GuruFocus